# BioAge Labs Inc. (BIOA)

Source: https://www.quantisnow.com/company/BIOA
Generated: 2026-11-19T00:55:07.337Z

- Ticker: BIOA
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2024
- SEC CIK: 0001709941

## Latest BIOA news and filings

- 2026-11-16 19:00 UTC [SEC Schedule 13G] [Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-bioage-labs-inc-6793695)
- 2026-11-11 13:00 UTC [Conference Announcement] [BioAge Labs to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/bioage-labs-to-present-at-upcoming-investor-conferences-6785236)
- 2026-11-05 21:40 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bioage-labs-inc-6777103)
- 2026-11-05 21:35 UTC [SEC Form 8-K] [BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioage-labs-inc-filed-sec-form-8-k-results-of-operations-6777058)
- 2026-11-05 21:30 UTC [Earnings] [BioAge Labs Reports Third Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/bioage-labs-reports-third-quarter-2026-financial-results-and-provides-6776905)
- 2026-11-02 21:14 UTC [BioArctic collaborator Novartis terminates agreement](https://www.quantisnow.com/insight/bioarctic-collaborator-novartis-terminates-agreement-6767206)
- 2026-10-30 14:20 UTC [BioArctic's Nomination Committee appointed](https://www.quantisnow.com/insight/bioarctics-nomination-committee-appointed-6764826)
- 2026-10-14 12:00 UTC [Deep Origin Announces Multi-Target AI-Driven Drug Discovery Collaboration with BioAge Labs; Validated Hits Confirmed against First Target](https://www.quantisnow.com/insight/deep-origin-announces-multi-target-ai-driven-drug-discovery-collaboration-with-bioage-6745906)
- 2026-10-12 12:47 UTC [Analyst Coverage Initiated] [UBS initiated coverage on BioAge Labs with a new price target](https://www.quantisnow.com/insight/ubs-initiated-coverage-on-bioage-labs-with-a-new-price-6743583)
- 2026-10-02 20:15 UTC [SEC Form 8-K] [BioAge Labs Inc. filed SEC Form 8-K: Other Events](https://www.quantisnow.com/insight/bioage-labs-inc-filed-sec-form-8-k-other-events-6734546)
- 2026-09-25 20:30 UTC [Conference Announcement] [BioAge Labs to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/bioage-labs-to-present-at-upcoming-investor-conferences-6726552)
- 2026-09-08 12:00 UTC [BioAge Labs Announces First Participant Dosed in QUELL-DME, a Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Diabetic Macular Edema](https://www.quantisnow.com/insight/bioage-labs-announces-first-participant-dosed-in-quell-dme-a-phase-6707527)
- 2026-09-02 12:00 UTC [Conference Announcement] [BioAge Labs to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/bioage-labs-to-present-at-upcoming-investor-conferences-6702367)
- 2026-08-31 15:56 UTC [Number of shares and votes in BioArctic AB (publ) as of August 31, 2026](https://www.quantisnow.com/insight/number-of-shares-and-votes-in-bioarctic-ab-publ-as-6699427)
- 2026-08-14 18:01 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-bioage-labs-inc-6682656)
- 2026-08-05 21:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bioage-labs-inc-6666154)
- 2026-08-05 20:55 UTC [SEC Form 8-K] [BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioage-labs-inc-filed-sec-form-8-k-results-of-operations-6666091)
- 2026-08-05 20:50 UTC [BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/bioage-labs-reports-second-quarter-2026-financial-results-and-provides-6666033)
- 2026-07-14 15:39 UTC [More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026](https://www.quantisnow.com/insight/more-than-75-of-leqembi-treated-patients-remained-stable-and-nearly-6636462)
- 2026-07-01 20:27 UTC [SEC Form 4] [Principal Accounting Officer Barton Shane exercised 59,934 shares at a strike of $6.58 and sold $1,576,752 worth of shares (62,566 units at $25.20) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/principal-accounting-officer-barton-shane-exercised-59934-shares-at-a-6623105)
- 2026-06-16 12:00 UTC [BioAge Labs Announces First Participant Dosed in QUELL-CV, a Phase 2 Proof-of-Concept Trial of BGE-102, a Novel Oral NLRP3 Inhibitor, in Patients at Elevated Cardiovascular Risk](https://www.quantisnow.com/insight/bioage-labs-announces-first-participant-dosed-in-quell-cv-a-phase-6603902)
- 2026-06-12 20:37 UTC [SEC Form 4] [SEC Form 4 filed by Director Pande Vijay Satyanand](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-pande-vijay-satyanand-6600771)
- 2026-06-12 20:35 UTC [SEC Form 4] [SEC Form 4 filed by Director Hemrajani Rekha](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-hemrajani-rekha-6600757)
- 2026-06-12 20:34 UTC [SEC Form 4] [SEC Form 4 filed by Director Healy James](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-healy-james-6600746)
- 2026-06-12 20:33 UTC [SEC Form 4] [SEC Form 4 filed by Director Enright Patrick G](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-enright-patrick-g-6600736)
- 2026-06-12 20:31 UTC [SEC Form 4] [SEC Form 4 filed by Director Davidson Michael H.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-davidson-michael-h-6600725)
- 2026-06-12 20:29 UTC [SEC Form 4] [SEC Form 4 filed by Director Garnier Jean Pierre](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-garnier-jean-pierre-6600642)
- 2026-06-12 12:00 UTC [SEC Form 8-K] [BioAge Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/bioage-labs-inc-filed-sec-form-8-k-submission-of-matters-6599577)
- 2026-05-27 13:00 UTC [Analyst Coverage Initiated] [Roth Capital initiated coverage on BioAge Labs with a new price target](https://www.quantisnow.com/insight/roth-capital-initiated-coverage-on-bioage-labs-with-a-new-6574108)
- 2026-05-22 13:00 UTC [Conference Announcement] [BioAge Labs to Present at Upcoming Investor Conferences](https://www.quantisnow.com/insight/bioage-labs-to-present-at-upcoming-investor-conferences-6569009)
- 2026-05-20 13:50 UTC [Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets](https://www.quantisnow.com/insight/cell-based-therapies-poised-to-disrupt-multi-billion-dollar-anti-aging-and-neurodegenerative-markets-6564627)
- 2026-05-15 17:18 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-bioage-labs-inc-6556687)
- 2026-05-14 13:00 UTC [Public Offering] [A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Avaí Bio's Cell-Based Platform Approach](https://www.quantisnow.com/insight/a-unique-klotho-based-anti-aging-therapy-to-be-introduced-at-a-6552804)
- 2026-05-13 12:08 UTC [Analyst Coverage Initiated] [BTIG Research initiated coverage on BioAge Labs with a new price target](https://www.quantisnow.com/insight/btig-research-initiated-coverage-on-bioage-labs-with-a-new-6549832)
- 2026-05-08 13:10 UTC [SEC Form 8-K] [BioAge Labs Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/bioage-labs-inc-filed-sec-form-8-k-results-of-operations-6541336)
- 2026-05-08 13:05 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-bioage-labs-inc-6541327)
- 2026-05-08 13:00 UTC [Public Offering] [BioAge Labs Reports First Quarter 2026 Financial Results and Provides Business Updates](https://www.quantisnow.com/insight/bioage-labs-reports-first-quarter-2026-financial-results-and-provides-6541289)
- 2026-05-04 20:30 UTC [BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026](https://www.quantisnow.com/insight/bioage-to-host-rd-day-focused-on-nlrp3-inhibition-on-6529329)
- 2026-04-24 20:19 UTC [SEC Form 4] [Chief Financial Officer Goldstein Dov A Md exercised 3,542 shares at a strike of $4.38, increasing direct ownership by 11% to 36,575 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-goldstein-dov-a-md-exercised-3542-shares-6514597)
- 2026-04-21 20:06 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by BioAge Labs Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-bioage-labs-inc-6508404)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/BIOA
- Earnings history: https://www.quantisnow.com/earnings/BIOA
- Dividend history: https://www.quantisnow.com/dividends/BIOA
- Insider transactions: https://www.quantisnow.com/insiders/BIOA
- Options chain: https://www.quantisnow.com/options/BIOA
- SEC 8-K filings only: https://www.quantisnow.com/company/BIOA/8-k
- RSS and alerts for BIOA: https://www.quantisnow.com/docs/rss-feeds.md
